General
Preferred name
CHLORZOXAZONE
Synonyms
Paraflex ()
Chlorzoxazon ()
Chlorzoxazon,Paraflex ()
Strifon ()
Parafon-Forte ()
Strifon Forte Dsc ()
NSC-26189 ()
Parafon Forte Dsc ()
Clorzoxazona ()
Parafon ()
Chlorzoxazone-d3 ()
P&D ID
PD002420
CAS
95-25-0
32850-84-3
1185173-60-7
Tags
available
drug
Approved by
FDA
First approval
1958
Drug indication
Acute pain
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Chlorzoxazone acts on the central nervous system to cause muscle relaxation and sedation.
(GtoPdb)
DESCRIPTION
Chlorzoxazone is a SK-type potassium channel activator. Chlorzoxazone modulates FOXO3 phosphorylation and A¦Â. Chlorzoxazone enhances immunosuppression, attenuates vasoconstriction, attenuates cognitive deficits, and improves experimental autoimmune encephalomyelitis[1][2][3][4][5][6][7][8][9][10].
PRICE
29
DESCRIPTION
Inducible nitric oxide synthetase inhibitor; skeletal muscle relaxant
(LOPAC library)
DESCRIPTION
Chlorzoxazone is a centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. Chlorzoxazone act by inhibiting calcium and potassium influx which would lead to neuronal inhibition and muscle relaxation.
(Enamine Bioactive Compounds)
DESCRIPTION
Chlorzoxazone (Chlorzoxazon) is a Muscle Relaxant. The physiologic effect of chlorzoxazone is by means of Centrally-mediated Muscle Relaxation.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
28
AdooQ Bioactive Compound Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
50
Molecular Weight
168.99
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
0
Ring Count
2
Aromatic Ring Count
2
cLogP
1.77
TPSA
46.0
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
iNOS
MOA
Unknown molecular target
bacterial 30S ribosomal subunit inhibitor
Target
Intermediate conductance calcium-activated potassium channel protein 4
Calcium-activated potassium channel subunit alpha-1
Cytochrome P450
Potassium Channel
KCNMA1, KCNN4
Amyloid-β
FOXO
P450 (e.g. CYP17)
Amyloid-¦Â
Indication
muscle relaxant
Therapeutic Class
Analgesics
Pathway
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
Neuronal Signaling
Metabolism
Source data
